Answers are grounded in this paper and cite their sources.
Medicine shortages continue to represent a critical global health challenge. While causes are multifactorial, issues can be mitigated by measures that increase manufacturing capacity. However, these require regulatory approval, often across multiple jurisdictions, and between-regulator differences in regulatory systems, data requirements and approval timelines can make global approval complex and time consuming. To address this challenge, the International Coalition of Medicines Regulatory Authorities (ICMRA) launched a pilot programme in which five submissions went through collaborative review of the same chemistry, manufacturing and control (CMC) data by up to eight global regulatory authorities, aiming to deliver harmonized outcomes using science and risk-based assessment principles. A standardized 120-day review process was established, enabling near-simultaneous approvals across participating regions. Most (88%) assessment questions were harmonized; alignment reduced the number of questions by 25% compared with independent reviews. These results demonstrate that global regulatory collaboration can significantly accelerate implementation of manufacturing changes, strengthen supply chains and help to mitigate medicine shortages. Efforts are underway to develop this into a sustainable global regulatory approach.
No takes yet. Share an insight, caveat, or question.
Barry et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: